In 2018, Morelos presents the mayor of the inquiry to a level national, with one una tasa of 100 investigators of 100 million inhabitants; the alberga entity the most important research centers that it generates, among other things, inventories of their relevance to the daily life of the citizens.
Morelos has one of the pioneering centers within the Mexican Institute of Social Security (IMSS) in the production of scientific articles and inventions that have been patented, the Center for Biomedical Investigation of the South (CIBIS), currently located in Xochenta 24 patents granted.
CIBIS is one of the five strategic centers that the IMSS has distributed throughout the country to cover its biomedical research; since 1985 its mission has been to generate scientific knowledge in the areas of Pharmacology, Phytochemistry, Biotechnology, Pharmaceutical Technology and Medicine for the development of safe and effective medicines in the treatment of the most frequent diseases.
Alejandro Zamilpa Álvarez, director of CIBIS, explains in his objective search solution to the main health problems of the Mexicans who identify the most frequent ones in the news for as long as the values are given to the system within 15 years ; the most studied have the problems of the central nervous system, dermatologists, diabetes, obesity and cancer, as long as they have a high incidence of research that is apparently in a technological development.
The CIBIS today has applied for a total of 32 patents, of which the Mexican Institute of Industrial Property (IMPI) has awarded a donation of 24, as well as to the IMSS biomedical research center with the mayor’s patent grant .
To put it bluntly, the doctor in chemistry mentions that in order to complete a technological development that can be subject to a protection process, it has to go through various stages of investigation, first understanding the basic investigation and identifying the positive ones. Solutions to the most common health problems of Mexican society.
All and all of CIBIS’s implications involve the use of standardized extracts in the active principles of plant species used in traditional Mexican medicine.
The second stage consists in the pharmaceutical design of each extract to generate the different presentations of the phytomedicines, the disciplines that participate in this stage, explained, are the Toxicology and the Pharmacocinetics that help to determine the safety, distribution.
The idea culminates in the clinical trials that will allow them to demonstrate the safety and therapeutic efficacy of these phytomedicines -drugs of herbal origin elaborated with standardized extracts-.
Biotechnology, says the researcher, helps to ensure the source of matter first in order to obtain a uniform production procedure for the plant species or its active principles.
Currently, only CIBIS investigations have directly benefited the volunteer patients who participated in their clinical trials; without embarrassment, when the institution generates the license to exploit these patents or decides to use them to generate their proprietary proposals, the Mexican company in general will benefit.
Some patents are registered on the same page: The use of active principles for the elimination of phytomedicines, as in the case of Galphimina B which is used for the production of anisolytic drugs, or the esteroidal saponin SC-2 which has demonstrated efficacy and safety of treatment (infection caused by hongos).
It also protects the use of plant species such as Solanum chrysotrichum and Mimosa tenuiflora to develop phytomedicines that help treat dermatological diseases and the gastrointestinal system, respectively.
The pharmaceutical preparations and extraction methods for obtaining active principles also have the object of patent application, as well as the biotechnological processes which allow to obtain extracts and active principles and also the procedures for obtaining extraction.
The Mayor of technological development includes a rigorous collaborative process between biologists, pharmacologists, chemists, biotechnologists and physicians, as well as external collaborations with specialized herbivores, by the future.
Although CIBIS has one of the patents, it has a large stake in involving many years of investigation, including a special case of a Galphimia glauca patent that includes the object of various premiums in the year of innovation.
CIBIS is compliant with a pool of investigators.